In this interactive panel discussion, oncology experts and a patient with small cell lung cancer (SCLC) discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.
Upon completion of this activity, participants should be better able to:
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair, Thoracic Malignancies
Fox Chase Cancer Center
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director, Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Druid Hills, GA
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources